NCT02390427 2026-04-09
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
Clinical Trials
291 trialsNCT02379416 2026-04-01
Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03798626 2026-04-01
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
Phase 1 Completed
NCT01374620 2026-03-16
PAL-ANGI2
Centre Oscar Lambret
Phase 1 Completed
NCT03725436 2026-03-16
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02195973 2026-02-09
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
University of Alabama at Birmingham
Phase 1 Completed
NCT06513364 2026-01-20
Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer
Beijing Wehand-Bio Pharmaceutical Co., Ltd
Phase 1 Completed
NCT03245892 2025-12-17
A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02621398 2025-12-16
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
Rutgers, The State University of New Jersey
Phase 1 Completed
NCT03595059 2025-12-10
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
AbbVie
Phase 1 Completed
NCT03177291 2025-12-05
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03279237 2025-11-25
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
Massachusetts General Hospital
Phase 1 Completed
NCT03564691 2025-10-07
MK-4830-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT04047862 2025-08-22
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
Phase 1 Completed
NCT02776917 2025-08-07
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer
University of California, San Diego
Phase 1 Completed
NCT02013154 2025-08-03
P102
Leap Therapeutics, Inc.
Phase 1 Completed
NCT03013218 2025-08-01
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
Phase 1 Completed
NCT04205903 2025-06-29
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT04608409 2025-06-29
Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer
University of Kentucky
Phase 1 Completed
NCT03918278 2025-06-25
MK-0482-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03535701 2025-06-08
KETO-CARE
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT03554044 2025-05-21
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
Phase 1 Completed
NCT00516724 2025-04-11
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
AstraZeneca
Phase 1 Completed
NCT03165955 2025-03-12
A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients
Health Hope Pharma
Phase 1 Completed
NCT01220154 2025-02-21
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02182245 2025-01-23
Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies
Boehringer Ingelheim
Phase 1 Completed
NCT03509012 2025-01-14
CLOVER
AstraZeneca
Phase 1 Completed
NCT02630823 2025-01-03
MK-3475 Immunotherapy in Endometrial Carcinoma
Washington University School of Medicine
Phase 1 Completed
NCT02723955 2024-12-27
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
Phase 1 Completed
NCT02794571 2024-12-05
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT02892123 2024-11-27
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Jazz Pharmaceuticals
Phase 1 Completed
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT03800836 2024-10-30
A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT03246074 2024-10-24
Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT02193633 2024-09-26
TAX-TORC
Royal Marsden NHS Foundation Trust
Phase 1 Completed
NCT05298592 2024-09-26
A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT03873883 2024-09-19
IO-001
iTeos Therapeutics
Phase 1 Completed
NCT03206177 2024-08-07
Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
University of Oklahoma
Phase 1 Completed
NCT00881166 2024-08-02
SGI-0470-02
Astex Pharmaceuticals, Inc.
Phase 1 Completed
NCT03154294 2024-07-26
Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors
Avera McKennan Hospital & University Health Center
Phase 1 Completed
NCT03292822 2024-06-20
Effects of (Licochalcone A) and Paclitaxel on Human Oral Squamous Cell Carcinoma Cell Line
Cairo University
Phase 1 Completed
NCT02312661 2024-05-06
OVMET
University Medical Center Groningen
Phase 1 Completed
NCT04551950 2024-03-08
Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
EMD Serono
Phase 1 Completed
NCT01946074 2023-12-15
A Study of ABT-165 in Subjects With Solid Tumors
AbbVie
Phase 1 Completed
NCT02672475 2023-11-22
Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT04473716 2023-11-22
Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients
Shanghai Jiao Tong University School of Medicine
Phase 1 Completed
NCT05519059 2023-11-22
Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer
Adlai Nortye Biopharma Co., Ltd.
Phase 1 Completed
NCT02231723 2023-11-18
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT02483247 2023-11-14
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT02599363 2023-11-09
A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed